Literature DB >> 2702778

Nuclear phosphotyrosyl-protein with DNA-binding ability in peripheral blood mononuclear cells from systemic lupus erythematosus patients.

Y Deguchi1, S Negoro, S Kishimoto.   

Abstract

This study examined the phosphorylation of cytoplasmic and nuclear proteins in peripheral blood mononuclear cells (PBMC) of systemic lupus erythematosus (SLE) patients. The cytoplasmic and nuclear protein kinase activity in PBMC from SLE patients was at least five-fold higher than that of normal healthy subjects. PBMC of SLE patients produced different nuclear endogenous substrates on phosphorylation and also displayed distinct protein kinase activity. Nuclear phosphoproteins, with human PBMC DNA-binding ability, of 38 kD and 70 kD were detected from both SLE patients and normal healthy subjects, while the 40 kD phosphoprotein, with tyrosine as the main phosphorylation residue, was found only in SLE patients. Other nuclear phosphoproteins, and most of the detected cytoplasmic phosphoproteins, were present in higher levels in both normal PBMC with mitogen stimulation, such as PHA, and SLE PBMC. The expression level of the 40 kD nuclear phosphotyrosyl-protein showed a positive correlation with the clinical disease activity of SLE. These results suggest that PBMC from SLE patients had distinct tyrosine protein kinase (TPK) activity and/or a different endogenous substrate of nuclear DNA-binding proteins in tyrosine phosphorylation. The possible significance of tyrosine phosphorylation in PBMC of SLE patients in the pathogenesis, and its clinical meaning, are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702778      PMCID: PMC1541940     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

Review 1.  Protein-tyrosine kinases.

Authors:  T Hunter; J A Cooper
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

2.  Virus- and cell-encoded tyrosine protein kinases inactivate DNA topoisomerases in vitro.

Authors:  Y C Tse-Dinh; T W Wong; A R Goldberg
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

3.  Isolation of a protein fraction that binds preferentially to chicken middle repetitive DNA.

Authors:  M Sanzo; B Stevens; M J Tsai; B W O'Malley
Journal:  Biochemistry       Date:  1984-12-18       Impact factor: 3.162

4.  Interleukin 2-dependent phosphorylation of interleukin 2 receptors and other T cell membrane proteins.

Authors:  G N Gaulton; D D Eardley
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

5.  Localization of a lymphocyte-specific protein tyrosine kinase gene (lck) at a site of frequent chromosomal abnormalities in human lymphomas.

Authors:  J D Marth; C Disteche; D Pravtcheva; F Ruddle; E G Krebs; R M Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

6.  Complement activation in systemic lupus erythematosus: a marker of inflammation.

Authors:  L D Kerr; B R Adelsberg; H Spiera
Journal:  J Rheumatol       Date:  1986-04       Impact factor: 4.666

7.  Equilibrium studies of the cyclic AMP receptor protein-DNA interaction.

Authors:  M G Fried; D M Crothers
Journal:  J Mol Biol       Date:  1984-01-25       Impact factor: 5.469

8.  Abnormal tyrosine phosphorylation on T-cell receptor in lymphoproliferative disorders.

Authors:  L E Samelson; W F Davidson; H C Morse; R D Klausner
Journal:  Nature       Date:  1986 Dec 18-31       Impact factor: 49.962

9.  Phorbol ester, calcium ionophore, or serum added to quiescent rat embryo fibroblast cells all result in the elevated phosphorylation of two 28,000-dalton mammalian stress proteins.

Authors:  W J Welch
Journal:  J Biol Chem       Date:  1985-03-10       Impact factor: 5.157

10.  Membranes from T and B lymphocytes have different patterns of tyrosine phosphorylation.

Authors:  H S Earp; K S Austin; S C Buessow; R Dy; G Y Gillespie
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.